Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Oct 10, 2025 (12 months ago)

R.E.C.K.

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Presence of Particulate Matter

Cause type: Particulate / foreign matter

Visible foreign particles - glass, metal, fibers or other material - found in the product. Particles can enter from equipment wear, containers or the process, and are dangerous in injectables. All particulate / foreign matter recalls.

What was recalled

R.E.C.K. (Ropivacaine HCl, EPINEPHrine, CloNIDine HCl, and Ketorolac Tromethamine) in Sodium Chloride Solution, Total Volume: 50 mL syringe. INJECTION FOR PERIARTICULAR USE; Not for IV Use. THIS IS A COMPOUNDED DRUG. QuVA Pharma, 1075 West Park One Drive, Suite 100, Sugar Land, TX 77478. NDC 70092-1433-50

Affected NDC 70092-1433-50

Compare with the code on your package — it is the most precise check available.

Drug: Epinephrine

Recalling firm
QuVa Pharma, Inc.
NDC code
70092-1433-50
Origin
TX, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0113-2026 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Epinephrine recalls

See all
Class I · High risk

Epinephrine Injection

Presence of Particulate Matter and Lack of Assurance of Sterility. Particulate matter identified as nylon, cellulosic, acrylic, polyethylene and glass and broken and leaking vials.

Ongoing Sterility / contamination American Regent, Inc. NDC 0517-3030-01 D-0865-2026
Class II · Moderate risk

Maximum

Stability Data Does Not Support Expiry Date.

Ongoing Stability / shelf life HTO Nevada Inc. dba Kirkman D-0387-2026

Other recalls by QuVa Pharma, Inc.

All 2025 recalls